Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662986 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBHSD17B10MEN1MAPK1 | |
| SCHEMBL4664925 | 0.85 | HPGD (0.46) | SMN1; SMN2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL4664730 | 0.84 | POLB (0.48) | SMN1; SMN2POLBHSD17B10MEN1MAPK1 | |
| SCHEMBL4662958 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBHSD17B10MEN1MAPK1 | |
| SCHEMBL4664983 | 0.80 | HPGD (0.52) | SMN1; SMN2POLBHSD17B10MEN1MAPK1 | |
| SCHEMBL4662964 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBHSD17B10MEN1KMT2A | |
| SCHEMBL4664653 | 0.77 | HSD17B10 (0.49) | HSD17B10MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL4662924 | 0.76 | LMNA (0.39) | SMN1; SMN2POLBMEN1MAPK1HTT | |
| SCHEMBL4663032 | 0.76 | PTPN1 (0.40) | POLBMEN1KMT2AALDH1A1CDC25A | |
| SCHEMBL4664866 | 0.76 | HPGD (0.43) | SMN1; SMN2MEN1HTTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | SMN1; SMN2 1277/4885POLB 1560/4885HSD17B10 1577/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | SMN1; SMN2 1277/4885POLB 1560/4885HSD17B10 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.